{"prompt": "['OSTPDL1', 'PROTOCOL SUMMARY', 'OSTPDL1, A Phase II Trial of Avelumab, a Fully Human Antibody that Targets', 'Cells Expressing PDL1 in Patients with Recurrent or Progressive', 'Osteosarcoma', 'Principal Investigator: Michael W. Bishop, MD, MS', \"IND holder: St. Jude Children's Research Hospital, IND# 132,874.\", 'Brief background and overview of study: Patients with recurrent or progressive', 'osteosarcoma have a poor overall survival rate and are unlikely to achieve cure', 'without complete surgical remission. The introduction of new cytotoxic and', 'biologic agents has failed to show efficacy in this population. Immunotherapy with', 'checkpoint inhibitors has demonstrated dramatic changes in outcomes in several', 'adult cancers and may provide greater benefit for tumors with high mutational', 'load. The purpose of this phase II study is to assess the efficacy of avelumab for', 'the treatment of patients with recurrent or progressive osteosarcoma who have', 'measurable residual disease.', 'Intervention: Single agent avelumab.', 'Brief outline of treatment plan: Patients will receive avelumab every 2 weeks in', 'cycles of 28 days for up to 24 months, or 26 cycles. Progression free survival and', 'response to therapy after 4 cycles of treatment will be assessed. In addition, the', 'toxicity profile of avelumab in this population will be closely monitored.', 'Study design: Multi-center phase II study.', 'Sample size: 32 evaluable patients; 40 total patients.', 'Data management: Data management and statistical analysis will be provided', 'locally by the Comprehensive Cancer Center Developmental Biology Solid Tumors', \"Program, and Biostatistics Department at St. Jude Children's Research Hospital.\", 'Human subjects: The main risk to research participants will be the potential', 'toxicities associated with the use of the investigational agent, avelumab. Research', 'participants will be informed of toxicities which have been associated with the', 'study drug and potential side effects of procedures recommended in this study.', 'Adverse events will be monitored, treated, and reported following institutional and', 'federal guidelines and regulations.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-3018 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'EXPERIMENTAL DESIGN SCHEMA', 'Unresected recurrent or', 'progressive osteosarcoma', 'Study entry', 'Cycle 1-2', 'Avelumab', 'Evaluation', 'Cycle 3-4', 'Stable', 'Avelumab', 'or', 'Progressive', 'Off protocol', 'disease or', 'Evaluation', 'therapy', 'unacceptable', 'toxicity (at any', 'Stable', 'Avelumab*', 'or', 'Continue every 2 weeks', 'for up to 24 months, or', 'Evaluation every 3', 'months', 'End protocol therapy', 'Progressive', 'disease or', 'Off protocol', 'therapy', 'unacceptable', '*Avelumab will be given on Days 1 & 15 of each 28 day cycle', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'TABLE OF CONTENTS', '1.0 OBJECTIVES', '1', '1.1', 'Primary Objectives', '1', '1.2', 'Secondary Objective', '1', '1.3', 'Exploratory Objectives', '1', '2.0 BACKGROUND AND RATIONALE', '1', '2.1', 'Background', '1', '2.2', 'Preclinical Studies', '4', '2.3', 'Clinical Studies', '6', '2.4', 'Rationale for this Study', '9', '2.5', 'Overview of Proposed Study', '9', '2.6', 'Rationale for Correlative Biology Studies', '9', '2.7', 'Rationale for Quality of Life Studies', '13', '3.0', 'ELIGIBILITY CRITERIA AND STUDY ENROLLMENT', '14', '3.1', 'Inclusion Criteria', '15', '3.2', 'Exclusion Criteria', '16', '3.3', 'Recruitment and Screening', '18', '3.4', 'Enrollment at St. Jude', '18', '3.5', 'Enrollment at Collaborating Sites', '18', '4.0 TREATMENT PLAN', '18', '4.1', 'Overview of Treatment Plan', '18', '4.2', 'Treatment During Cycle 1 and Subsequent Cycles', '18', '5.0 DOSE MODIFICATIONS FOR TOXICITIES', '20', '5.1 Adverse Drug Reactions Requiring Avelumab Discontinuation or', 'Modification', '20', '5.2', 'Treatment Modification for Symptoms of Infusion-Related Reactions .21', '5.3', 'Management of Immune-Mediated Adverse Reactions', '22', '5.4', 'Autoimmune or Immune System Disorders Affecting Other Organ', 'Systems', '28', '5.5', 'Central Venous Catheter', '28', '5.6', 'Concomitant Therapy', '28', '6.0 DRUG INFORMATION', '28', '6.1', 'Avelumab (MSB0010718C, anti-PD-L1)', '28', '7.0 REQUIRED EVALUATIONS, TESTS, AND OBSERVATIONS', '29', '7.1', 'Evaluations Before and During Therapy', '29', '7.2', 'Extended Safety Follow-up', '31', '8.0 CORRELATIVE RESEARCH STUDIES', '31', '8.1', 'Tumor Tissue', '31', '8.2', 'Immunologic Research - NCI Testing Battery', '31', '8.3', 'Immunologic Research - St. Jude Testing Battery', '35', '9.0 EVALUATION CRITERIA', '37', '9.1', 'Response Definitions and Criteria for Solid Tumors', '37', '9.2', 'Response Criteria for Patients with Solid Tumor and Measurable Disease', '40', '9.3', 'Response Criteria for Evaluable Disease', '41', '9.4', 'Best Response', '41', '9.5', 'Duration of Response', '42', 'St: Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 IRB APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}